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Insulin resistance in mice lacking 
neuronal nitric oxide synthase is related 
to an alpha-adrenergic mechanism
P. Turinia, S. Thalmanna, P.-Y. Jayet a, S. Cooka, C. Mathieua, R. Burcelin b, P. Nicoda, P. Vollenweider a, 
C. Sartori a,1, U. Scherrer a,1
a Department of Internal Medicine and Botnar Center for Clinical Research, CHUV, Lausanne,
Switzerland 
b CHU Rangueil, Toulouse, France
Background: nitric oxide (NO) plays an impor-
tant role in the regulation of cardiovascular and
glucose homeostasis. Mice lacking the gene en-
coding the neuronal isoform of nitric oxide syn-
thase (nNOS) are insulin-resistant, but the under-
lying mechanism is unknown. nNOS is expressed
in skeletal muscle tissue where it may regulate
glucose uptake. Alternatively, nNOS driven NO
synthesis may facilitate skeletal muscle perfusion
and substrate delivery. Finally, nNOS dependent
NO in the central nervous system may facilitate
glucose disposal by decreasing sympathetic nerve
activity. 
Methods: in nNOS null and control mice, we
studied whole body glucose uptake and skeletal
muscle blood flow during hyperinsulinaemic
clamp studies in vivo and glucose uptake in skele-
tal muscle preparations in vitro. We also exam-
ined the effects of alpha-adrenergic blockade
(phentolamine) on glucose uptake during the
clamp studies. 
Results: as expected, the glucose infusion rate
during clamping was roughly 15 percent lower in
nNOS null than in control mice (89 (17) vs 101
(12) [–22 to –2]). Insulin stimulation of muscle
blood flow in vivo, and intrinsic muscle glucose
uptake in vitro, were comparable in the two
groups. Phentolamine, which had no effect in the
wild-type mice, normalised the insulin sensitivity
in the mice lacking the nNOS gene.
Conclusions: insulin resistance in nNOS null
mice was not related to defective insulin stimula-
tion of skeletal muscle perfusion and substrate de-
livery or insulin signaling in the skeletal muscle
cell, but to a sympathetic alpha-adrenergic mech-
anism.
Key words: nitric oxide; neuronal nitric oxide syn-
thase; insulin resistance; sympathetic nerve activity;
muscle blood flow; intrinsic muscle glucose uptake
Summary
Metabolic insulin resistance is a problem of
major clinical importance. Epidemiological ob-
servations demonstrate an association between in-
sulin resistance and cardiovascular disease [1–4],
but the mechanism relating these disorders is not
known. Nitric oxide (NO) plays an important role
in the regulation of metabolic and cardiovascular
homeostasis in experimental animal models and
humans. In humans, altered NO synthesis and/or
bioavailability is associated with cardiovascular
disease [5–8] and insulin resistance [7, 9], and may
represent a link between these two disease states.
Studies in mice indicate that each of the three ni-
tric oxide synthase (NOS) isoforms play a role in
the regulation of glucose homeostasis. Endothe-
lial nitric oxide synthase (eNOS) null mice are
 hypertensive and insulin resistant [10, 11]. The
latter appears to be caused by impaired insulin
stimulation of blood flow and substrate delivery
to skeletal muscle tissue, mitochondrial dysfunction
[12, 13] and an intrinsic defect of muscle glucose
uptake [11]. Partial deletion of the eNOS gene
(eNOS+/-) predisposes to exaggerated high-fat-
diet-induced arterial hypertension and insulin re-
sistance in mice, demonstrating an important 
interaction between environmental and genetic
factors in the regulation of cardiovascular and
glucose homeostasis [14]. iNOS null mice do not
Introduction
This work was
 supported by
grants from the
Swiss National
 Science Founda-
tion, the Fondation
Romande pour la
Recherche sur le
 Diabète, the Cloëtta
Foundation, the
Emma Muschamp
Foundation, the
CardioMet Founda-
tion and the Placide
Nicod Foundation.
1 C.S and U.S.
 contributed 
equally to this 
work.
700-704 Turini 11950-07.qxp  17.12.2007  9:01 Uhr  Seite 700
701S W I S S  M E D  W K LY 2 0 0 7 ; 13 7 : 7 0 0 – 7 0 4  ·  w w w. s m w. ch
develop high-fat-diet-induced insulin resistance,
indicating that iNOS-driven NO synthesis con-
tributes to insulin resistance in this model [15].
Neuronal NOS (nNOS) dependent NO also
appears to play a role in the regulation of insulin
sensitivity, since nNOS null mice are insulin re-
sistant [16], but the underlying mechanisms are
unknown. nNOS could modulate insulin sensitiv-
ity in several ways. It is highly expressed in skele-
tal muscle tissue [17], where it may facilitate glu-
cose uptake. Alternatively, nNOS derived NO
could modulate insulin sensitivity by regulating
skeletal muscle perfusion and substrate delivery,
which are NO dependent [18, 19]. Finally, nNOS
derived NO inhibits central [20–22] neural sym-
pathetic outflow and counteracts sympathetic vas-
cular and metabolic effects in skeletal muscle 
tissue [23–25]. Sympathetic overactivity is as-
sociated with insulin resistance in animals and 
humans [2, 9]. Thus, nNOS derived NO could
exert beneficial effects on insulin sensitivity by de-
creasing sympathetic activity. 
To test these hypotheses, we measured, in
nNOS null and control mice, insulin stimulated
whole body glucose uptake and skeletal muscle
blood flow during euglycaemic hyperinsulinaemic
clamp studies in vivo, and basal and insulin stimu-
lated glucose uptake in isolated skeletal muscle
preparations in vitro. We also tested the effects of
alpha-adrenergic blockade on whole body glucose
uptake during clamp studies in these two groups
of animals.  
Methods
All protocols were approved by the Institutional An-
imal Care and Use Committee.
nNOS null C57BL6 mice, generated as previously
described [16], were used. nNOS null and control mice
were generated by mating heterozygous animals from our
colony. Ten to 14 week old male and female mice of gen-
eration 9 to 12 were used for the studies. 
Hyperinsulinaemic euglycaemic clamp studies
Euglycaemic hyperinsulinaemic clamps in freely
moving mice were performed as described previously
[11]. 16 nNOS null and 18 control mice were studied.
Briefly, on the day of the clamp, after a 6-hour fast, insulin
was infused (18 mU/kg per min, a dose known to suppress
hepatic glucose production) [11, 14] into the femoral vein
for 150 minutes. Throughout the clamp, blood samples
were collected every 5 minutes from the tip of the tail to
determine the blood glucose concentration. Euglycaemia
(5.5 (SD 0.5) mmol/L) was maintained by periodic ad-
justment of a variable infusion of 15% glucose. The
steady state glucose infusion rate was calculated as the
mean of the values obtained every 5 minutes during the
last 30 minutes of the clamp. 
Identical studies were performed in 13 knockout and
5 control mice following the intraperitoneal injection of
phentolamine (20 mg/kg, a dose known to prevent the in-
crease in arterial blood pressure evoked by the a-ad -
renergic agonist phenylephrine) [26] 20 minutes before
starting the clamp. 
Muscle blood flow
Insulin stimulation of muscle blood flow was meas-
ured in anesthetized mice (4 nNOS null, 7 control mice)
during a 90-minute glucose clamp with a laser Doppler
probe (Perimed, Periflux System 5000, Probe #403, 
Sweden) inserted into the hindlimb skeletal musculature
as described previously [11]. The body temperature was
maintained at 37.5 ± 0.5 °C with a temperature control
unit (Frederick Haer and Co., Bowdoinham, ME). The
blood flow signal was recorded on a personal computer
using specific data acquisition software (Powerlab 400,
AD).
Figure 1
Glucose infusion
rates during euglyc -
aemic hyperinsulin -
aemic clamp studies
in control (squares)
and in nNOS null 
(circles) mice in the
absence (filled sym-
bols; n = 18 control
and 16 nNOS null
mice) and the pres-
ence (open symbols;
n = 5 control and 
13 nNOS null mice)
of alpha-adrenergic
blockade. Data are
the mean with bars
showing the standard
error of the mean 
(P <0.001, for group
and time effects as
well as for their inter-
action: ANOVA be-
tween nNOS null
without phento-
lamine and both
nNOS null mice with
phentolamine and
wild type mice). 
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Glucose utilisation in isolated skeletal muscle
After cervical dislocation, the soleus and EDL mus-
cles were rapidly isolated, tied separately to silk threads
by the tendons and immersed for 20 minutes in an incu-
bation medium (Krebs-Ringer bicarbonate [pH 7.35]
supplemented with 0.1% bovine serum albumin [Frac-
tion V, pH 7.0] and 2 mM sodium pyruvate) [11]. Under
an atmosphere containing 5% CO2 and 95% O2, the mus-
cles were then incubated for an additional 60 minutes at
37 °C in this medium, in the presence or absence of 20 nM
insulin. Thereafter, the muscles were immersed for 
20 minutes in the incubation medium supplemented with
3H-2-deoxyglucose (0.1 mM, 1 μCi/ml). During this im-
mersion the 3H-2-deoxyglucose is metabolised to 3H-2-
deoxyglucose-6-phosphate. To stop the reaction, the
muscles were immersed in ice-cold saline buffer, washed
for 30 minutes and then dissolved in NaOH 1M at 60 °C
for 60 minutes. An aliquot of the extract was spun down
and the 3H-labeled radioactivity was counted in the pres-
ence of a scintillation buffer. Sample aliquots were used
for protein determination. Soleus muscles of 8 nNOS
null and 4 control mice, and EDL muscles of 4 nNOS
null and 6 control mice, were studied.
Measurement of arterial blood pressure
Blood pressure was measured in awake, partially re-
stricted mice (10 nNOS null and 6 control mice) with
fluid filled PE-10 tubing connected to a pressure trans-
ducer, as described previously [11]. Blood pressure values
were averaged over a 20 minute period.
Analytical methods
Fasting blood glucose and insulin (ELISA, Mer -
codia, Uppsala, Sweden) plasma concentrations were
measured in conscious mice (n ≥9 for each group) after 
a 5-hour fast. Free fatty acids (n ≥8 for each group) 
were measured after a 5-hour fast by colorimetric enzy-
matic determination (NEFA-C, Wako).
Statistical analysis
Data were analysed with the JMP software package
(SAS Institute Inc., Gary, North Carolina, USA), using
the confidence interval for difference between means for
single comparisons. Data are presented as mean (standard
deviation) and compared using a 95% confidence interval
for the difference between group means [95% confidence
interval]. For the comparison of the glucose infusion
rates during euglycaemic hyperinsulinaemic clamp stud-
ies (figure 1) we used a two-way analysis of variance
(ANOVA) for repeated measures on one way (time) for
assessing solution and time effects, as well as their inter-
action. Bonferroni correction was used to avoid bias due
to multiple comparisons. Symmetrical distribution of all
the data was confirmed using the Shapiro-Wilk test for
normality.
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Insulin stimulation of
muscle blood flow at
the end of a 90-min -
ute hyperinsulin -
aemic euglycaemic
clamp in 4 nNOS null
and 7 control mice.
Horizontal lines rep-
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Figure 3
Basal and insulin
stimulated 2-deoxy -
glucose uptake in
soleus and EDL mus-
cle of nNOS null
(filled symbols) and
control (open sym-
bols) mice. Soleus
muscles of 8 knock-
out and 4 control
mice and EDL mus-
cles of 4 knockout
and 6 control mice
were studied. 95%
confidence interval
for the difference be-
tween group means:
[–0.01 to 0.07] (basal)
and [–0.12 to 0.09]
(insulin) for the
soleus muscle. [–0.07
to 0.04] (basal) and 
[–0.04 to 0.09] (insu -
lin) for the EDL mus-
cle. Horizontal lines
represent means.
Body weight (20.9 (2.9) vs 20.9 (1.9) g), fast-
ing plasma glucose (5.6 (0.4) vs 5.5 (0.4) mmol/L),
insulin (16 (8) vs 18 (7) μU/ml), and free fatty acid
concentration (1.0 (0.3) and 0.9 (0.3) mmol/L)
were comparable in nNOS null and control mice. 
As expected, the nNOS null mice were insulin
resistant (figure 1), as evidenced by a roughly 
15 percent lower glucose infusion rate during the
last 30 minutes of the clamp (89 (17) vs 101 (12) 
[–22 to –2]. During the clamp studies, the glucose
(5.6 (0.4) vs 5.5 (0.4) mmol/L) and insulin plasma
concentration (340 (120) vs 320 (50) μU/ml) were
comparable in nNOS null and control mice.
To determine whether insulin resistance in
the nNOS-/- mice was related to a defect in in-
sulin stimulation of skeletal muscle perfusion,
which is NO dependent,[18] we measured skele-
tal muscle blood flow during clamp studies. We
found that the increase in muscle blood flow at
the end of the clamp was comparable in the
nNOS null and the control mice (37 (14) vs 43
(19) [–29 to 16]) % (figure 2). Mean arterial blood
pressure (109 (5) vs 107 (13) [–8 to 11] mm Hg)
was also comparable in the nNOS null and con-
trol mice. 
nNOS is highly expressed in skeletal muscle
tissue. To test whether nNOS deficiency may im-
pair skeletal muscle glucose uptake, we measured
glucose uptake in isolated soleus and EDL muscle
in vitro. The basal and insulin stimulated muscle
deoxyglucose uptake were comparable in the
nNOS null and the control mice (figure 3). 
Results
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Over the past decade, evidence has accumu-
lated indicating that nitric oxide generated by
each of the three NOS isoforms plays an impor-
tant role in the regulation of glucose homeostasis,
but it is not known, whether this regulation in-
volves isoform-specific mechanisms or not. Here
we found that insulin resistance in nNOS null
mice was related to a sympathetic mechanism, be-
cause alpha-adrenergic blockade normalised in-
sulin sensitivity in the nNOS null mice, whereas it
had no detectable effect in the control mice.
These findings indicate that NOS isoforms regu-
late glucose homeostasis by different mechanisms. 
The insulin resistance of the nNOS null mice
in the present studies was of similar magnitude to
the level reported by Shankar and colleagues [16].
In eNOS null mice, insulin resistance is related, at
least in part, to an intrinsic defect of skeletal mus-
cle glucose uptake [11]. This mechanism does not
appear to contribute to insulin resistance in
nNOS null mice, because basal and insulin stimu-
lated skeletal muscle glucose uptake in vitro were
comparable in nNOS null and control mice. This
surprising finding suggests that NO generated by
nNOS, which is abundantly expressed in skeletal
muscle tissue [17], does not appear to be essential
for maintaining normal glucose homeostasis in
this tissue. Impaired insulin stimulation of blood
flow and substrate delivery to skeletal muscle tis-
sue, which are NO-dependent [18], are additional
mechanisms contributing to insulin resistance in
eNOS null mice [11]. In the present study, we
found that insulin stimulation of skeletal muscle
blood flow during the clamp studies was compa-
rable in the two groups, suggesting that vascular
function is preserved in nNOS null mice. Consis-
tent with this hypothesis, arterial blood pressure
was also comparable in the two groups. 
nNOS-derived NO inhibits central sympa-
thetic outflow and counteracts sympathetic vaso-
constriction in skeletal muscle tissue [20, 21, 23],
and sympathetic overactivity is associated with in-
sulin resistance in animals and humans [7, 27]. To
test for the involvement of adrenergic mecha-
nisms in the insulin resistance of nNOS null mice,
we examined the effects of phentolamine on in-
sulin stimulated whole body glucose uptake in the
two groups of mice. We found that alpha-adren-
ergic blockade normalised insulin sensitivity in
the nNOS null mice, whereas it had no detectable
effect in the control mice. This finding suggests
that sympathetic overactivity, possibly related to
the loss of central neural inhibition of sympa-
thetic outflow by nNOS-derived NO, contributes
to insulin resistance in nNOS null mice. In line
with this hypothesis, intracerebroventricular in-
jection of L-NMMA in rats causes insulin resist-
ance by a central neural action [21].
Taken together with earlier observations, the
present findings indicate that, in mice, defective
NO synthesis causes insulin resistance by differ-
ent mechanisms, depending on the NOS iso -
enzyme involved. Whereas in eNOS null mice,
insulin resistance is related to defects in insulin
stimulation of muscle perfusion and insulin sig-
nalling in the skeletal muscle cell [11], in nNOS
null mice these mechanisms do not appear to play
an important role, and sympathetic mechanisms
appear to be the main culprit. Insulin resistant
states in humans are associated with defective NO
synthesis and/or impaired NO bioavailability, and
with sympathetic over-activity [7, 9]. Moreover,
a-adrenergic blockade has been shown to im-
prove insulin sensitivity in insulin resistant sub-
jects [28]. We speculate that loss of central neural
inhibition of sympathetic outflow by NO may
also represent a mechanism contributing to in-
sulin resistance and its associated cardiovascular
complications in humans.
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Discussion
Loss of nNOS-dependent NO may result in
increased central neural sympathetic outflow that
could induce insulin resistance. Therefore, we ex-
amined the effects of alpha-adrenergic blockade
on insulin-stimulated glucose uptake during
clamp studies. Phentolamine significantly in-
creased the glucose infusion rate in the nNOS
null mice (from 89 (17) to 102 (14) [1 to 25]
mg/kg/min), whereas it had no detectable effect
on the glucose infusion rate in the control mice
(101 (12) vs 101 (13) [–13 to 12] mg/kg/min) 
(figure 1). After phentolamine, the glucose infu-
sion rates were comparable in the nNOS null and
control mice (102 (14) vs 101 (12) [–8 to 11]
mg/kg/min). 
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